Ltx-109 clinical trials
Also written LTX-109.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses ltx-109 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LTX-109
- 2
Studies by the year they started
5 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2013 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses ltx-109 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus AureusCompletedPhase 2Pharma Holdings ASNCT05889351Written as LTX-109 3% gel, 4 + 4 applications
- Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.Status unknownPhase 2Pharma Holdings ASNCT04854928Written as LTX-109 gel, 3%
- A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in ImpetigoCompletedPhase 2Lytix Biopharma ASNCT01803035Written as LTX-109 1 %
- A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)CompletedPhase 1/2Lytix Biopharma ASNCT01158235Written as LTX-109
- A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin InfectionCompletedPhase 2Lytix Biopharma ASNCT01223222Written as LTX-109
Codes
What other systems call ltx-109 · ClinicalTrials.gg INT005932
- UNII (FDA) HO813QDF65VOXVOGANANConfirmed FDA, NLM, Wikidata
- Wikidata Q27147342ltx-109Confirmed FDA, NLM, Wikidata
- DrugBank DB12711One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HO813QDF65 | VOXVOGANAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27147342 | ltx-109 | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB12711 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.